Sunitinib promotes apoptosis via p38 MAPK activation and STAT3 downregulation in oral keratinocytes
Oral Diseases · 2024-03 · 30 (2) · 639-649
DOI: 10.1111/odi.14457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 04.01.2023. Verfasst von Shohei Fukada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Hiromi Nishi, Kouji Ohta.
Abstract (Originalsprache)
Objective
Sunitinib, a targeted cancer drug, inhibits tyrosine kinases receptors and is widely used as first‐line treatment for metastatic renal cell carcinoma. Patients undergoing chemotherapy with sunitinib frequently have oral mucosal complications, such as oral stomatitis, though cytotoxic effects of the drug on oral keratinocytes remain unknown.
Methods
The effects of sunitinib on immortalized oral keratinocytes, RT7 cells, in regard to cell injury and apoptosis, as well as apoptosis‐mediated signaling pathways were investigated.
Results
Sunitinib treatment caused a significant increase in lactate dehydrogenase (LDH) in RT7 cells and primary oral keratinocytes. Additionally, the drug induced apoptosis‐related events, such as DNA fragmentation, decreased anti‐apoptotic Bcl‐2 protein expression, and induction of cleaved PARP and caspase 3/9 in RT7 cells. Furthermore, phosphorylation of p38 MAPK, but not of ERK or JNK, was increased. On the contrary, constitutive phosphorylated STAT3 was decreased by sunitinib treatment, which was recovered by exposure to SB203580, a p38 MAPK inhibitor. Finally, SB203580 was found to reduce sunitinib‐induced cell injury and apoptosis.
Conclusion
The present results indicate that sunitinib promotes cell injury and apoptosis in oral keratinocytes via p38 activation and STAT3 downregulation. Sunitinib‐mediated oral complications may be associated with cytotoxic effects of the drug on oral keratinocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Public Oral Health, Program of Oral Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Dentistry, Oral and Maxillofacial Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
- Department of General Dentistry, Hiroshima University Hospital, Hiroshima, Japan.
ORCID-Profile: Shohei Fukada, Kouji Ohta, Misaki Akagi
Förderung
- Hiromi Nishi
- Kouji Ohta
Zitieren
APA
Fukada, S., Ohta, K., Sakuma, M., Akagi, M., Kato, H., Naruse, T., Nakagawa, T., Shigeishi, H., Nishi, H., Takechi, M., & Aikawa, T. (2024). Sunitinib promotes apoptosis via p38 MAPK activation and STAT3 downregulation in oral keratinocytes. Oral Diseases, 30(2), 639-649. https://doi.org/10.1111/odi.14457
Vancouver
Fukada S, Ohta K, Sakuma M, Akagi M, Kato H, Naruse T, et al. Sunitinib promotes apoptosis via p38 MAPK activation and STAT3 downregulation in oral keratinocytes. Oral Diseases. 2024;30(2):639-649. doi:10.1111/odi.14457
BibTeX
@article{Fukada2024,
author = {Fukada, Shohei and Ohta, Kouji and Sakuma, Miyuki and Akagi, Misaki and Kato, Hiroki and Naruse, Takako and Nakagawa, Takayuki and Shigeishi, Hideo and Nishi, Hiromi and Takechi, Masaaki and Aikawa, Tomonao},
title = {Sunitinib promotes apoptosis via p38 MAPK activation and STAT3 downregulation in oral keratinocytes},
journal = {Oral Diseases},
year = {2024},
volume = {30},
number = {2},
pages = {639--649},
doi = {10.1111/odi.14457}
}
EUVIMED